Lordstown aims to boost EV production with Foxconn investment, seeks new automaker partner

Lordstown aims to boost EV production with Foxconn investment, seeks new automaker partner


Signage outside Lordstown Motors Corp. headquarters in Lordstown, Ohio, on Saturday, May 15, 2021.

Dustin Franz | Bloomberg | Getty Images

Struggling electric truck startup Lordstown Motors still plans to deliver the first examples of its Endurance pickup truck before the end of the year, the company said Tuesday, a day after it announced a new investment from Taiwanese contract manufacturer Foxconn.

Lordstown said that it is now building the Endurance at “a very slow rate” while it works to build out its assembly line and awaits final regulatory approval to sell the trucks. The company now expects to build about 30 pickups for sale by year-end, and to complete the remainder of the first batch of 500 trucks by the end of June 2023.

Lordstown said in late September that it hoped to build 50 trucks by year-end. To date, it has completed 12 trucks.

Lordstown’s shares were up over 15% in premarket trading on Tuesday.

The company said late on Monday that Foxconn, which already owns a stake in Lordstown and bought its Ohio factory for $230 million in May, will invest an additional $170 million in three phases, with the first $52.7 million due later this month. Once those investments are completed, Foxconn will own about 18% of Lordstown and will have the right to designate two members of its board of directors.

Lordstown said it will use part of that investment to develop a new vehicle together with Foxconn. The companies had previously announced a joint venture to develop a new model; the new funding replaces that joint venture.

The investment helps address a lack of capital that has hindered Lordstown’s efforts to get the Endurance into production.

Lordstown previously told investors that its first batch of Endurance pickups will be limited to a maximum of 500 vehicles because the cost of building a pickup is currently “materially higher” than the company’s expected selling price. Additional investments in manufacturing tooling would bring the cost down, but CEO Edward Hightower has deferred those investments to preserve cash.

Lordstown said on Tuesday that it is actively seeking an automaker partner to help scale up production of the Endurance.

The updates came as part of Lordstown’s third-quarter earnings report. Lordstown, which doesn’t yet record revenue, reported a net loss of $154.4 million, or 73 cents a share, including nearly $75 million in non-cash accounting charges related to the sale of its factory to Foxconn.

The company had $204 million in cash remaining as of quarter-end.



Source

CDC says there are no U.S. hantavirus cases currently, 41 people being monitored
Business

CDC says there are no U.S. hantavirus cases currently, 41 people being monitored

In this photo illustration Hantavirus samples are seen in Ankara, Turkiye on May 6, 2026. Arman Onal | Anadolu | Getty Images The U.S. Centers for Disease Control and Prevention said there are no hantavirus cases in the country as of Thursday, as it monitors 41 people for the virus. The agency said the risk […]

Read More
These three artworks could sell for 0 million each next week as May auctions begin
Business

These three artworks could sell for $100 million each next week as May auctions begin

A large-scale Jackson Pollock drip painting titled, “Number 7A, 1948.” Crystal Lau | CNBC A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. Nearly $2 billion worth of art will come up […]

Read More
Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data
Business

Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data

A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Biogen plans to advance an experimental drug for Alzheimer’s disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday. Biogen said its experimental drug that targets tau, a protein associated with the memory-robbing disease, failed to show better responses at higher doses. […]

Read More